Expertise in
14
conditions

Dr. Brian C. Baumann

Radiation Oncology
Office
900 N 1st St, 
Springfield, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
14
conditions
Office
900 N 1st St, 
Springfield, IL 

Overview

Brian Baumann is a Radiation Oncologist practicing medicine in Springfield, Illinois.

Dr. Baumann is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and Merkel Cell Carcinoma.

He is actively involved in clinical research, co-authoring 111 peer reviewed articles and participating in 10 clinical trials. Dr. Baumann is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in MO

Hospital Affiliations

Barnes Jewish Hospital
St Lukes Hospital
Memorial Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Office
900 N 1st St, Springfield, IL 62702
Other Locations
Gaines & Banday LLC
301 N 8th St, Springfield, IL 62701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
Enrollment Status: Recruiting
Publish Date: March 11, 2026
Intervention Type: Radiation
Study Phase: Phase 1/Phase 2
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
Intervention Type: Procedure, Biological, Drug, Other, Radiation
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine, Fluorouracil, Mitomycin C
Study Phase: Phase 2
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drug: Paclitaxel
Study Phase: Phase 1/Phase 2
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Enrollment Status: Terminated
Publish Date: April 12, 2022
Intervention Type: Other
Study Phase: Not Applicable
View 8 Less Clinical Trials

111 Total Publications

Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
Similar Doctors
Expertise in
23
conditions
Dr. Christopher M. Bradbury
Radiation Oncology
Expertise in
23
conditions
Dr. Christopher M. Bradbury
Radiation Oncology
Referral may be required

Springfield Memorial Hospital

701 N 1st St, 
Springfield, IL 
 (0.1 miles away)
217-528-7541
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Bradbury is a Radiation Oncologist practicing medicine in Springfield, Illinois. Dr. Bradbury is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Pleuropulmonary Blastoma, and Squamous Cell Lung Carcinoma. Dr. Bradbury is currently accepting new patients.

Expertise in
10
conditions
Dr. Parashar J. Nanavati
Radiation Oncology
Expertise in
10
conditions
Dr. Parashar J. Nanavati
Radiation Oncology
Referral may be required

Springfield Clinic LLP

1025 S 6th St, 
Springfield, IL 
 (1.4 miles away)
Languages Spoken:
English
See accepted insurances

Parashar Nanavati is a Radiation Oncologist practicing medicine in Springfield, Illinois. Dr. Nanavati is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Vulvar Cancer, and Pleuropulmonary Blastoma.

Expertise in
20
conditions
Dr. Harold A. Yoon
Radiation Oncology
Expertise in
20
conditions
Dr. Harold A. Yoon
Radiation Oncology
Referral may be required

Office

210 W McKinley Ave Ste 2, 
Decatur, IL 
 (35.8 miles away)
217-877-9442
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harold Yoon is a Radiation Oncologist practicing medicine in Decatur, Illinois. Dr. Yoon is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, Small Cell Lung Cancer (SCLC), and Lung Cancer. Dr. Yoon is currently accepting new patients.

Frequently Asked Questions about Dr. Brian C. Baumann

How do I make an appointment with Dr. Brian C. Baumann?

You can book an appointment with Dr. Brian C. Baumann by calling their office at 217-528-7541. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brian C. Baumann a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brian C. Baumann is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brian C. Baumann specialize in?

While Dr. Brian C. Baumann is a Radiation Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Brian C. Baumann participate in research or clinical trials?

Yes. Dr. Brian C. Baumann has published 111 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Brian C. Baumann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brian C. Baumann accept my insurance?

Dr. Brian C. Baumann accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 217-528-7541 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baumann's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile